Navigation Links
Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
Date:6/25/2008

- Significant Milestone Achieved Based on Compelling Clinical Studies -

Company to Host Roundtable Conference Call on July 15

FREMONT, Calif., June 25 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, today announced that it has submitted a 510(k) pre-market notification application to the U.S. Food & Drug Administration (FDA) requesting regulatory clearance of its Ovarian Tumor Triage Test known as OVA1(TM).

As announced previously, the OVA1 prospective clinical trial met its primary endpoints, indicating that the test is capable of stratifying women with pelvic masses into high- and low-risk categories to help determine whether the patient should be referred to a specialist prior to surgery. The clinical trial was one of the largest ovarian cancer studies ever conducted and assessed more than 550 women with a confirmed adnexal mass at 27 clinical sites in the United States. Additionally, the trial was the culmination of more than eight independent studies in more than 2500 women.

"The OVA1 test will help assess the risk of malignancy in the hundreds of thousands of women who require surgery for ovarian tumors each year. This information can be used to identify those who might benefit from referral to a gynecologic oncologist," said Fred Ueland, M.D., principal investigator of the study and Associate Professor of Gynecologic Oncology at the University of Kentucky. "While most tumors are benign, numerous studies have shown that women with ovarian cancer have better overall outcomes when their surgery is performed by a gynecologic oncologist."

"This is an important milestone for Vermillion and a significant step toward the commercialization of OVA1. We are ple
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vermillion and the Ohio State University Report That Novel Diagnostic Test May Help Predict Risk for Relapse of TTP, A Serious Blood Disorder
2. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
3. Vermillion Receives Award From the Society of Gynecologic Oncologists
4. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
7. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
8. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
9. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
10. AdvanDx Submits Yeast Traffic Light PNA FISH(TM) for FDA 510(k) Clearance for Detection of Candida species in Positive Blood Cultures
11. Cardica Reports Positive Top-Line Results and Submits 510(k) for PAS-Port(R) Proximal Anastomosis System in Cardiac Bypass Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 Reportlinker.com announces that ... in its catalogue: Wireless Opportunities ... Zigbee, UWB WWAN, WMAN, WLAN and other ... Kalorama Information,s Wireless Opportunities in ... UWB WWAN, WMAN, WLAN and other technologies) ...
(Date:8/20/2014)... , Aug. 20, 2014   Ventana ... Roche  Group, today announced that its VENTANA System ... marked in the European Union for routine pathology, ... system, consisting of VENTANA Virtuoso software coupled with ... iScan HT slide scanner, provides automated digital slide ...
(Date:8/20/2014)... Aug. 20, 2014  Decision Resources Group ... and ablation device market will expand through ... treat atrial fibrillation (AF). The increasing acceptance ... for AF will spur adoption of premium-priced ... as advanced loop diagnostic catheters, cryoablation catheters ...
Breaking Medicine Technology:Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 2Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 3Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 4Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 5Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 6Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 7Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 8Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 9Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 10Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 11Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 12Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 13Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 14Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 15Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 16Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3
... Dec. 8 Halozyme Therapeutics, Inc.,(Nasdaq: HALO ... extracellular matrix, today announced that Roche has,dosed the first ... a,subcutaneous formulation using Enhanze Technology of a biologic directed ... payment under the,agreement. , ...
... Positive Opinion for TEMODAL(R) Intravenous Formulation and Oral TEMODAL ... EU Patients with Certain Primary Brain Tumors , ... Schering-Plough Corporation (NYSE: SGP ) today ... Use (CHMP) of the European Medicines Agency (EMEA) has ...
Cached Medicine Technology:Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target 2Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target 3Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target 4CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors 2CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors 3CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors 4CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors 5CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors 6
(Date:8/20/2014)... 2014 IQ Formulations , a top ... the Inc. 500 , distinguishing it as one of ... Formulations not only made the list, but was ranked in ... the past three years. It also ranked ninth among all ... and the second fastest growing company in the Miami metro ...
(Date:8/20/2014)... It’s no secret that millions of ... National Institute on Drug Abuse, nearly 24 million Americans ... more alarming is the fact that the total number ... Those locked in a struggle with substance abuse often ... now, the newly-redesigned AbuseTreatmentCenters.net has released updated lists of ...
(Date:8/20/2014)... The Institute for Integrative Nutrition ... to announce its new partnership with California ... university offering graduate programs featuring flexible learning. Graduates ... now eligible to receive six graduate credits towards ... , “I’m so thrilled to announce this new ...
(Date:8/20/2014)... 2014 A Missouri federal judge has remanded ... were treated with GranuFlo and NaturaLyte to the City of ... Baron and Budd. The judge rejected an assertion by the ... were invalid. (McGee, et al. v. Fresenius Medical Care North ... Medical Care, is the manufacturer of the dialysis products GranuFlo ...
(Date:8/20/2014)... 2014 Botanica Day Spa ... Utilizing the new and popular stem cell line ... lines and wrinkles and naturally repairs the skin. ... the new service by offering clients a complimentary ... cell facial. , Pevonia® continues to be a ...
Breaking Medicine News(10 mins):Health News:Leading Health Supplement Company IQ Formulations Among Inc. Magazine’s Top 50 Fastest Growing Private Companies in the United States 2Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 2Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 3Health News:GranuFlo/NaturaLyte Case Remanded to State Court By Missouri Federal Judge, Baron and Budd Reports 2Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 2Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 3
... say , WEDNESDAY, Nov. 21 (HealthDay News) -- ... certain sounds, such as the sound of a familiar voice ... Washington, Seattle, and the University of California, Los Angeles, ... activity associated with a given sound task can also identify ...
... vascular disease is widespread and often deadly among older ... treat it, according to a new report by a ... Center and Weill Cornell Medical College campuses of NewYork-Presbyterian ... fact that for years, cardiovascular research has focused almost ...
... Revenues Increase 89% to $3.51 Million versus $1.85 ... Million for Q3 of 2006, -- Third ... ... /Xinhua-PRNewswire-FirstCall/ -- China Yingxia,International, Inc. (OTC Bulletin Board: CYXI), a leading provider in ...
... Eclipsys Corporation(R),(Nasdaq: ECLP ), The Outcomes ... Merrill Lynch Health Services Investor Conference,taking place next ... http://www.newscom.com/cgi-bin/prnh/20050209/FLW006LOGO ), Eclipsys executives will present ... a.m. Eastern time. Interested parties are invited to,listen ...
... 21 Shamir,Optical Industry Ltd. (Nasdaq: SHMR ) ... on Tuesday, November 27, 2007, and has,scheduled a conference ... that,morning., The conference call will be broadcast live ... http://www.kcsa.com approximately five minutes before,the conference call ...
... best value for money, study finds , WEDNESDAY, Nov. 21 ... and programs to improve the quality and value of their ... 21 issue of the Journal of the American Medical ... 609 executives of the largest employers in 41 U.S. ...
Cached Medicine News:Health News:Arterial vascular disease underdiagnosed, undertreated in older US women 2Health News:Arterial vascular disease underdiagnosed, undertreated in older US women 3Health News:Arterial vascular disease underdiagnosed, undertreated in older US women 4Health News:China Yingxia International Announces 2007 Third Quarter Financial Results Conference Call 2Health News:China Yingxia International Announces 2007 Third Quarter Financial Results Conference Call 3Health News:China Yingxia International Announces 2007 Third Quarter Financial Results Conference Call 4Health News:China Yingxia International Announces 2007 Third Quarter Financial Results Conference Call 5Health News:Eclipsys to Present at the Merrill Lynch Health Services Investor Conference 2Health News:Eclipsys to Present at the Merrill Lynch Health Services Investor Conference 3Health News:Shamir Optical Industry Ltd. to Host Conference Call Announcing Third Quarter 2007 Earnings Results 2Health News:Most U.S. Companies Do Little to Boost Worker Health Benefits 2
... Calvin Klein Collection. Provocatively inspired for ... a bold outlook. Innovative structure: soft-sculpted ... technology enhances modern design. Technological sophistication ... enhance the face., ,The Calvin Klein ...
... Marc Jacobs is ... very first collection in ... unveiling a range of ... that are defined by ...
... new GUCCI DONNA eyewear collection celebrates the ... a vintage yet contemporary feel, the unmistakable ... new GUCCI UOMO optical and sunglass collection, ... classic lines with cutting-edge design that is ...
The Alexander McQueen eyewear collection focuses on a distinctive sophisticated style, with feminine lines, assertive shapes and original silhouettes....
Medicine Products: